Good evening :)
Place Order
Add to Watchlist

Sun Pharma Advanced Research Co Ltd

SPARC Share Price

158.840.29% (-0.46)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹5,154 cr, stock is ranked 773

Stock is 3.45x as volatile as Nifty

SPARC Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Low

Profitability and efficiency haven't been upto the mark

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹5,154 cr, stock is ranked 773

Stock is 3.45x as volatile as Nifty

SPARC Performance & Key Metrics

SPARC Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-15.0540.99
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.156.590.81%

SPARC Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

SPARC Company Profile

Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy).

Investor Presentation

View older View older 

Dec 24, 2024

PDF
View Older Presentations

SPARC Similar Stocks (Peers)

Compare with peers Compare with peers 

SPARC Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.80
36.80
1Y Return
7.60%
7.60%
Buy Reco %
87.88
87.88
PE Ratio
23.18
23.18
1Y Return
2.20%
2.20%
Buy Reco %
73.33
73.33
PE Ratio
59.65
59.65
1Y Return
17.34%
17.34%
Buy Reco %
70.83
70.83
PE Ratio
19.24
19.24
1Y Return
0.89%
0.89%
Buy Reco %
55.17
55.17
PE Ratio
22.26
22.26
1Y Return
11.97%
11.97%
Buy Reco %
44.44
44.44
Compare with Peers

SPARC Forecast

SPARC Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

SPARC

SPARC

Income

Balance Sheet

Cash Flow

SPARC Income Statement

SPARC Income Statement

Loading...

Financial YearFY 2023FY 2024FY 2025TTM
Total Revenue249.66105.0273.5673.56
Raw Materialssubtract0.000.00394.91394.91
Power & Fuel Costsubtract5.756.14
Employee Costsubtract107.00141.84
Selling & Administrative Expensessubtract289.71267.06
Operating & Other expensessubtract50.3862.60
Depreciation/Amortizationsubtract11.7712.5112.3912.39
Interest & Other Itemssubtract7.631.699.049.04
Taxes & Other Itemssubtract0.000.38-0.27-0.27
EPS-6.86-11.93-10.55-10.55
DPS0.000.000.000.00
Payout ratio0.000.000.000.00

SPARC Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

Dec 24PDF
Dec 19PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Oct 28PDF
Oct 17PDF
Oct 13PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Dec 28PDF
Dec 16PDF
Dec 9PDF
FY 2021FY 2021

Annual report

PDF

Investor Presentation

Sep 10PDF
FY 2020FY 2020

Annual report

PDF

Investor Presentation

Sep 19PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

SPARC Stock Peers

SPARC Past Performance & Peer Comparison

SPARC Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sun Pharma Advanced Research Co Ltd-15.0540.99
Sun Pharmaceutical Industries Ltd36.805.990.95%
Cipla Ltd23.183.911.06%
Torrent Pharmaceuticals Ltd59.6516.630.95%

SPARC Stock Price Comparison

Compare SPARC with any stock or ETF
Compare SPARC with any stock or ETF
SPARC
Loading...

SPARC Holdings

SPARC Shareholdings

SPARC Promoter Holdings Trend

SPARC Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SPARC Institutional Holdings Trend

SPARC Institutional Holdings Trend

Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.29%

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SPARC Shareholding Pattern

SPARC Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding65.67%1.01%0.12%1.45%31.75%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

SPARC Shareholding History

SPARC Shareholding History

Dec '23MarJunSepDec '24Mar0.24%0.25%0.08%0.10%0.51%1.01%

Mutual Funds Invested in SPARC

Mutual Funds Invested in SPARC

No mutual funds holding trends are available

Top 5 Mutual Funds holding Sun Pharma Advanced Research Co Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.2343%1.16%0.48%27/47 (+16)
0.1117%0.24%0.24%302/318 (0)
0.0005%0.01%0.00%653/816 (0)

Compare 3-month MF holding change on Screener

SPARC Insider Trades & Bulk Stock Deals

SPARC Insider Trades & Bulk Stock Deals

Loading...

smallcases containing SPARC stock

smallcases containing SPARC stock

Looks like this stock is not in any smallcase yet.

SPARC Events

SPARC Events

SPARC Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SPARC has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

SPARC Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SPARC has not given any dividends in last 5 years

SPARC Dividends

SPARC Dividends

Hmm, looks like data is unavailable here. Please come back after some time

SPARC Stock News & Opinions

SPARC Stock News & Opinions

Spotlight
SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials

In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Sun Pharma Advanced Research Company Ltd leads losers in 'A' group

Aditya Birla Fashion & Retail Ltd, Fusion Finance Ltd Partly Paidup, Alivus Life Sciences Ltd and Indo Count Industries Ltd are among the other losers in the BSE's 'A' group today, 04 June 2025.Sun Pharma Advanced Research Company Ltd lost 18.76% to Rs 158.9 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9.45 lakh shares were traded on the counter so far as against the average daily volumes of 94359 shares in the past one month.Aditya Birla Fashion & Retail Ltd crashed 10.33% to Rs 77.1. The stock was the second biggest loser in 'A' group.On the BSE, 437.77 lakh shares were traded on the counter so far as against the average daily volumes of 4.25 lakh shares in the past one month.Fusion Finance Ltd Partly Paidup tumbled 3.89% to Rs 100.05. The stock was the third biggest loser in 'A' group.On the BSE, 985 shares were traded on the counter so far as against the average daily volumes of 10093 shares in the past one month.Alivus Life Sciences Ltd dropped 3.48% to Rs 1024. The stock was the fourth biggest loser in 'A' group.On the BSE, 2773 shares were traded on the counter so far as against the average daily volumes of 5155 shares in the past one month.Indo Count Industries Ltd fell 3.43% to Rs 271.3. The stock was the fifth biggest loser in 'A' group.On the BSE, 16635 shares were traded on the counter so far as against the average daily volumes of 54599 shares in the past one month.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 59.77 crore in the March 2025 quarter

Net Loss of Sun Pharma Advanced Research Company reported to Rs 59.77 crore in the quarter ended March 2025 as against net loss of Rs 105.79 crore during the previous quarter ended March 2024. Sales rose 64.19% to Rs 27.19 crore in the quarter ended March 2025 as against Rs 16.56 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 342.51 crore in the year ended March 2025 as against net loss of Rs 387.21 crore during the previous year ended March 2024. Sales declined 5.00% to Rs 71.77 crore in the year ended March 2025 as against Rs 75.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales27.1916.56 64 71.7775.55 -5 OPM %-195.59-639.07 --450.24-532.23 - PBDT-57.72-102.34 44 -330.39-374.32 12 PBT-60.67-105.41 42 -342.78-386.83 11 NP-59.77-105.79 44 -342.51-387.21 12 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Sun Pharma Advanced Research Company to table results

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
SPARC submits application for its ADC to US FDA to conduct global phase-1 study

The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors. Antibody'drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumours. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv. Anil Raghavan, CEO of SPARC, said: SBO-154, our first ADC is ready to advance in phase-1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally. Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The scrip had declined 2.63% to end at Rs 148 on the BSE on Friday. Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Sun Pharma Advanced Research Company submits IND application to USFDA

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors. 'SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.' said Anil Raghavan, CEO of SPARC. SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Volumes jump at Sun Pharma Advanced Research Company Ltd counter

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 79.51 crore in the December 2024 quarter

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.51 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales14.9113.86 8 OPM %-494.23-740.40 - PBDT-76.30-96.49 21 PBT-79.44-99.65 20 NP-79.51-99.65 20 Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Sun Pharma Advanced Research Company reports standalone net loss of Rs 79.71 crore in the December 2024 quarter

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.71 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales14.9113.86 8 OPM %-498.86-740.40 - PBDT-76.96-96.49 20 PBT-79.71-99.65 20 NP-79.71-99.65 20 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Sun Pharma Advanced Research Company to hold board meeting

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Sun Pharma Advanced Research Co Ltd (SPARC) today?

    The share price of SPARC as on 4th July 2025 is ₹158.84. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Sun Pharma Advanced Research Co Ltd (SPARC) share?

    The past returns of Sun Pharma Advanced Research Co Ltd (SPARC) share are
    • Past 1 week: -0.13%
    • Past 1 month: -10.85%
    • Past 3 months: 9.14%
    • Past 6 months: -17.56%
    • Past 1 year: -34.61%
    • Past 3 years: -22.55%
    • Past 5 years: -3.03%

  3. What are the peers or stocks similar to Sun Pharma Advanced Research Co Ltd (SPARC)?
  4. What is the market cap of Sun Pharma Advanced Research Co Ltd (SPARC) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharma Advanced Research Co Ltd (SPARC) is ₹5154.70 Cr as of 4th July 2025.

  5. What is the 52 week high and low of Sun Pharma Advanced Research Co Ltd (SPARC) share?

    The 52-week high of Sun Pharma Advanced Research Co Ltd (SPARC) is ₹258 and the 52-week low is ₹109.30.

  6. What is the PE and PB ratio of Sun Pharma Advanced Research Co Ltd (SPARC) stock?

    The P/E (price-to-earnings) ratio of Sun Pharma Advanced Research Co Ltd (SPARC) is -15.05. The P/B (price-to-book) ratio is 40.99.

  7. Which sector does Sun Pharma Advanced Research Co Ltd (SPARC) belong to?

    Sun Pharma Advanced Research Co Ltd (SPARC) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Sun Pharma Advanced Research Co Ltd (SPARC) shares?

    You can directly buy Sun Pharma Advanced Research Co Ltd (SPARC) shares on Tickertape. Simply sign up, connect your demat account and place your order.